ATE509629T1 - Kombination von iap-inhibitoren und flt3- inhibitoren - Google Patents
Kombination von iap-inhibitoren und flt3- inhibitorenInfo
- Publication number
- ATE509629T1 ATE509629T1 AT07868853T AT07868853T ATE509629T1 AT E509629 T1 ATE509629 T1 AT E509629T1 AT 07868853 T AT07868853 T AT 07868853T AT 07868853 T AT07868853 T AT 07868853T AT E509629 T1 ATE509629 T1 AT E509629T1
- Authority
- AT
- Austria
- Prior art keywords
- combination
- inhibitors
- iap
- flt3
- active agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86744806P | 2006-11-28 | 2006-11-28 | |
US89108807P | 2007-02-22 | 2007-02-22 | |
PCT/US2007/085579 WO2008067280A2 (en) | 2006-11-28 | 2007-11-27 | Combination of iap inhibitors and flt3 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE509629T1 true ATE509629T1 (de) | 2011-06-15 |
Family
ID=39386468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07868853T ATE509629T1 (de) | 2006-11-28 | 2007-11-27 | Kombination von iap-inhibitoren und flt3- inhibitoren |
Country Status (20)
Country | Link |
---|---|
US (1) | US8492429B2 (de) |
EP (1) | EP2089024B1 (de) |
JP (1) | JP5394249B2 (de) |
KR (1) | KR20090087094A (de) |
AT (1) | ATE509629T1 (de) |
AU (1) | AU2007325280B2 (de) |
BR (1) | BRPI0719543A2 (de) |
CA (1) | CA2670498A1 (de) |
CO (1) | CO6210722A2 (de) |
EC (1) | ECSP099472A (de) |
GT (1) | GT200900142A (de) |
IL (1) | IL198551A0 (de) |
MA (1) | MA30966B1 (de) |
MX (1) | MX2009005621A (de) |
NO (1) | NO20092417L (de) |
PL (1) | PL2089024T3 (de) |
PT (1) | PT2089024E (de) |
RU (1) | RU2456983C2 (de) |
TN (1) | TN2009000206A1 (de) |
WO (1) | WO2008067280A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Birドメイン結合化合物 |
BRPI0617751A2 (pt) | 2005-10-25 | 2011-08-02 | Aegera Therapeutics Inc | compostos de ligação do domìnio iap bir |
TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
WO2008014236A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2009140447A1 (en) | 2008-05-16 | 2009-11-19 | Novartis Ag | Immunomodulation by iap inhibitors |
US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
WO2011098904A1 (en) | 2010-02-12 | 2011-08-18 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
US20140243276A1 (en) | 2011-09-30 | 2014-08-28 | Tetralogic Pharmaceuticals Corporation | Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
CA2913189C (en) | 2013-06-25 | 2020-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Method of treating intracellular infection |
WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
MX2021010115A (es) | 2019-02-22 | 2021-09-21 | Hanmi Pharm Ind Co Ltd | Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda. |
KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
CA3130244A1 (en) | 2019-02-22 | 2020-08-27 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
US11198699B2 (en) | 2019-04-02 | 2021-12-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
WO2021220178A1 (en) | 2020-04-29 | 2021-11-04 | Cominnex Zrt. | Iap antagonists and their therapeutic applications |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1453661A1 (ru) * | 1972-11-17 | 1989-10-30 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Противоопухолевое средство "продимин |
CA2491041A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
JP4691549B2 (ja) * | 2004-04-07 | 2011-06-01 | ノバルティス アーゲー | Iapの阻害剤 |
EP2606933A3 (de) * | 2005-12-20 | 2014-10-15 | Novartis AG | Kombination eines IAP inhibitors und eines Taxanes |
PE20110224A1 (es) * | 2006-08-02 | 2011-04-05 | Novartis Ag | PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO |
-
2007
- 2007-11-27 AT AT07868853T patent/ATE509629T1/de active
- 2007-11-27 CA CA002670498A patent/CA2670498A1/en not_active Abandoned
- 2007-11-27 US US12/516,062 patent/US8492429B2/en not_active Expired - Fee Related
- 2007-11-27 JP JP2009539434A patent/JP5394249B2/ja not_active Expired - Fee Related
- 2007-11-27 EP EP07868853A patent/EP2089024B1/de active Active
- 2007-11-27 PL PL07868853T patent/PL2089024T3/pl unknown
- 2007-11-27 MX MX2009005621A patent/MX2009005621A/es active IP Right Grant
- 2007-11-27 RU RU2009124590/15A patent/RU2456983C2/ru not_active IP Right Cessation
- 2007-11-27 PT PT07868853T patent/PT2089024E/pt unknown
- 2007-11-27 BR BRPI0719543-5A patent/BRPI0719543A2/pt not_active IP Right Cessation
- 2007-11-27 KR KR1020097013350A patent/KR20090087094A/ko active IP Right Grant
- 2007-11-27 WO PCT/US2007/085579 patent/WO2008067280A2/en active Application Filing
- 2007-11-27 AU AU2007325280A patent/AU2007325280B2/en not_active Ceased
-
2009
- 2009-05-04 IL IL198551A patent/IL198551A0/en unknown
- 2009-05-22 TN TNP2009000206A patent/TN2009000206A1/fr unknown
- 2009-05-27 GT GT200900142A patent/GT200900142A/es unknown
- 2009-06-03 MA MA31946A patent/MA30966B1/fr unknown
- 2009-06-24 NO NO20092417A patent/NO20092417L/no not_active Application Discontinuation
- 2009-06-25 CO CO09066298A patent/CO6210722A2/es not_active Application Discontinuation
- 2009-06-26 EC EC2009009472A patent/ECSP099472A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2008067280A2 (en) | 2008-06-05 |
AU2007325280A1 (en) | 2008-06-05 |
KR20090087094A (ko) | 2009-08-14 |
PT2089024E (pt) | 2011-08-31 |
JP5394249B2 (ja) | 2014-01-22 |
AU2007325280B2 (en) | 2011-03-10 |
ECSP099472A (es) | 2009-10-30 |
PL2089024T3 (pl) | 2011-10-31 |
EP2089024A2 (de) | 2009-08-19 |
CA2670498A1 (en) | 2008-06-05 |
US20100056467A1 (en) | 2010-03-04 |
IL198551A0 (en) | 2010-02-17 |
WO2008067280A3 (en) | 2008-08-07 |
EP2089024B1 (de) | 2011-05-18 |
MX2009005621A (es) | 2009-06-12 |
GT200900142A (es) | 2010-06-24 |
JP2010511059A (ja) | 2010-04-08 |
CO6210722A2 (es) | 2010-10-20 |
RU2009124590A (ru) | 2011-01-10 |
BRPI0719543A2 (pt) | 2014-02-25 |
NO20092417L (no) | 2009-08-25 |
TN2009000206A1 (en) | 2010-10-18 |
US8492429B2 (en) | 2013-07-23 |
MA30966B1 (fr) | 2009-12-01 |
RU2456983C2 (ru) | 2012-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE509629T1 (de) | Kombination von iap-inhibitoren und flt3- inhibitoren | |
MX2009005551A (es) | Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda. | |
MX2009006877A (es) | Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos. | |
TW200833662A (en) | 4,5-ring annulated indole derivatives and methods of use thereof | |
MX2009000285A (es) | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. | |
HK1124546A1 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
GEP20125691B (en) | Compounds and compositions as protein kinase inhibitors | |
MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
ZA200701629B (en) | Gyrase inhibitors and uses thereof | |
DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
MX2010002296A (es) | Inhibidores iv de polimerasa de fosfadiazina hcv. | |
MX2008008556A (es) | Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. | |
WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
BRPI0212298B8 (pt) | composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico | |
AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
WO2007044325A3 (en) | Apoe4 domain interaction inhibitors and methods of use thereof | |
WO2006128740A3 (en) | Anti-vascular methods and therapies employing lysyl oxidase inhibitors | |
DE602005010203D1 (de) | Pharmazeutische zusammensetzung enthaltend 2,4-dichlorbenzylalkohol und amylmetakresol | |
MXPA04005033A (es) | Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes. | |
WO2006091222A3 (en) | Methods of treating and preventing severe acute respiratory syndrome (sars) with avr118 | |
WO2021080188A3 (ko) | 단백질 발현 억제제를 포함하는 우울증의 예방 또는 치료용 조성물 및 이의 용도 | |
AU2016219620A1 (en) | Compositions and methods useful for treatment of respiratory illness | |
MXPA05011593A (es) | Composicion farmaceutica que comprende un inhibidor de catepsina s y un opioide. | |
EP1769789A3 (de) | Capsaicin enthaltende topische Zusammensetzung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 2089024 Country of ref document: EP |